G

GSK

Develops medicines, vaccines, and consumer health

Access Optimization Lead - Hepatology / Immunology

Full-Time
No salary listed
Senior
Bachelor's, Master's, MBA, PharmD
Philadelphia, PA, USA+1 moreMore locations: Durham, NC, USA
HybridSpecific on-site expectations will be discussed during the interview process.
Business & StrategyCorporate Strategy

About the job

Requirements
  • A bachelor's degree is required.
  • At least 5 years of relevant experience in pharmaceutical or biotechnology market access, access strategy, payer marketing, reimbursement, pricing and contracting, brand strategy, or related commercial roles is required.
  • Experience developing and leading market access strategies is required.
  • Experience working across payers, providers, health systems, organized customers, and channel partners is required.
  • Demonstrated ability to lead cross-functional strategy in a matrixed organization is required.
  • Strong strategic thinking, communication, and influencing skills, including the ability to influence without authority, are required.
Responsibilities
  • Serve as the market access strategy lead for assigned brands, accountable for integrated access strategy across payer, provider, patient support, pricing and contracting, trade and distribution, and organized customer segments.
  • Act as the primary Market Access representative on the Integrated Brand Commercialization Team, shaping brand strategy and embedding access considerations in commercial decisions, launch plans, lifecycle planning, and performance discussions.
  • Develop and own the market access strategy, including strategic choices to optimize access, brand growth, financial performance, and customer pull-through.
  • Lead development of the brand's access perspective within the integrated brand plan, annual operating plan, and long-range strategic planning.
  • Translate customer, competitor, policy, reimbursement, and market signals into recommendations that evolve the value proposition, evidence needs, strategic priorities, and tactical plan.
  • Partner with pricing and contracting, analytics, health economics and outcomes research, patient experience, account teams, and trade/channel teams to evaluate tradeoffs across investments, gross-to-net implications, customer strategies, and launch/lifecycle priorities.
  • Lead cross-functional alignment around access strategy and coordinate the broader market access matrix against business priorities.
  • Provide access guidance to brand and senior leadership on competitive events, reimbursement changes, payer and provider dynamics, organized customer trends, and emerging risks and opportunities.
  • Inform development of customer-facing resources, evidence communication, segment strategies, and field guidance.
  • Support launch readiness and lifecycle optimization for new brands, new indications, and portfolio priorities.
  • Build relationships across the organization and serve as a strategic advisor on market access issues.
Desired Qualifications
  • An advanced degree such as an MBA, Master of Public Health, Master of Science, or Doctor of Pharmacy is preferred.
  • Experience supporting launches, relaunches, or new indication launches is preferred.
  • Experience with Commercial, Medicare, Medicaid, hospital, integrated delivery network, health system, and organized customer strategy is preferred.
  • Experience with 340B, site-of-care dynamics, and provider channel strategy is preferred.
  • Experience interpreting and developing market access strategies for major United States market and reimbursement policy evolutions, such as most-favored-nation policy, the Inflation Reduction Act, and benefit design changes, is preferred.
  • Demonstrated ability to synthesize quantitative analysis and qualitative insight into strategic recommendations is preferred.
  • Experience making tradeoff decisions across competing initiatives, finite budgets, and gross-to-net or access investment considerations is preferred.
  • Strong executive communication and presentation skills are preferred.
  • Experience managing agencies, third-party vendors, and strategic projects is preferred.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Company News

Pattern of USA
Oct 12th, 2026
GSK Commits $800 Million to Enhance Biologics Manufacturing Facilities in Pennsylvania

GSK Commits $800 Million to Enhance Biologics Manufacturing Facilities in Pennsylvania 10/12/2026

Yahoo Finance
Oct 9th, 2026
GSK to invest $800M in Pennsylvania biopharma hub, creating 300 jobs

GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a biopharmaceutical manufacturing and research hub, creating over 300 jobs in the next five years, Pennsylvania Governor Josh Shapiro's office announced on Friday. The expansion will combine drug manufacturing, research and development, quality testing, and digital operations in Montgomery County. Construction is planned to begin in 2027 and will support clinical and commercial production of biologic medicines. The project will include a commercial-scale biologics manufacturing facility, a research pilot plant, and a centralised quality-control laboratory. It will also retain approximately 4,500 existing full-time jobs in Pennsylvania. Combined with GSK's previously announced Lancaster County facility, the company's planned investment in Pennsylvania totals nearly $1.7 billion.

Global Banking & Finance Review
Oct 9th, 2026
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs.

Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs. Posted on October 9, 2026 · Last updated: October 9, 2026 GSK to invest over $800 million in Pennsylvania biopharma hub, create 300 jobs. GSK's major expansion in Pennsylvania. Overview of the investment. Oct 9 (Reuters) - GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday. Key features of the new biopharma hub. * The investment will establish a site that combines drug manufacturing, research and development, quality testing and digital operations in Montgomery County. * GSK said construction is planned to begin in 2027 and the project will support both clinical and commercial production of biologic medicines. * The expansion is expected to create more than 300 new jobs and retain about 4,500 existing full-time jobs in Pennsylvania. * The company said the project will include a new commercial-scale biologics manufacturing facility, a research pilot plant and a centralized quality-control laboratory. Economic impact and incentives. * Pennsylvania officials said GSK will be eligible for state manufacturing tax incentives tied to the investment. * The Upper Merion expansion and GSK's previously announced Lancaster County facility project together represent nearly $1.7 billion of planned investment in Pennsylvania, according to state officials. * GSK, whose U.S. headquarters is in Philadelphia, said the expansion will help accelerate the development and supply of future medicines. Reporting credits. (Reporting by Sahil Pandey in Bengaluru; Editing by Anil D'Silva) Key takeaways. * GSK's $800M-plus expansion in Upper Merion expands capabilities across manufacturing, R&D, QC and digital operations and is part of a broader $1.7B investment in PA alongside Lancaster project. * The project supports both clinical and commercial biologic production, with construction slated for 2027, and helps retain more than 4,500 existing Pennsylvania full-time jobs. * State incentives - including manufacturing tax credits - and prior GSK investments in Lancaster contribute to reinforcing Pennsylvania's life-sciences leadership. Frequently asked questions. What is GSK investing in Pennsylvania? How many jobs will GSK's investment create in Pennsylvania? What facilities will be included in GSK's Upper Merion expansion? When is construction expected to begin for GSK's biopharma hub? What incentives is GSK eligible for with this investment?

TokenPost
Oct 9th, 2026
GSK plans more than $800 million expansion in Pennsylvania.

GSK plans more than $800 million expansion in Pennsylvania. The Montgomery County project is expected to add about 300 jobs over the next five years. Published Oct 9, 2026, 2:46 PM EDT GSK plc (GSK) plans to invest more than $800 million to expand its operations in Montgomery County, Pennsylvania, with the project expected to add about 300 jobs over the next five years. Discover more Ethereum investment guide Stablecoin investment platform Accept Payments The investment will expand GSK's operations in Pennsylvania. The expansion is planned over the next five years, with the new jobs tied to the company's Montgomery County operations. John Kim. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to [email protected].

Salem Radio Network
Oct 9th, 2026
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs.

Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs. Oct 9 (Reuters) - GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday. - The investment will establish a site that combines drug manufacturing, research and development, quality testing and digital operations in Montgomery County. - GSK said construction is planned to begin in 2027 and the project will support both clinical and commercial production of biologic medicines. - The expansion is expected to create more than 300 new jobs and retain about 4,500 existing full-time jobs in Pennsylvania. - The company said the project will include a new commercial-scale biologics manufacturing facility, a research pilot plant and a centralized quality-control laboratory. - Pennsylvania officials said GSK will be eligible for state manufacturing tax incentives tied to the investment. - The Upper Merion expansion and GSK's previously announced Lancaster County facility project together represent nearly $1.7 billion of planned investment in Pennsylvania, according to state officials. - GSK, whose U.S. headquarters is in Philadelphia, said the expansion will help accelerate the development and supply of future medicines. (Reporting by Sahil Pandey in Bengaluru; Editing by Anil D'Silva)